Atossa Therapeutics, Inc. (ATOS) Financials

ATOS Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2023 101.7 million 3.4 million
June 30, 2023 108.4 million 3.5 million
March 31, 2023 116.2 million 2.9 million
Dec. 31, 2022 123.5 million 5.6 million

ATOS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -3.9 million 926000
June 30, 2023 -4.5 million 1.6 million
March 31, 2023 -7.0 million 1.6 million
Dec. 31, 2022 -4.5 million 1.5 million

ATOS Net Income

No data available :(

ATOS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 94.0 million - -
June 30, 2023 99.4 million - -
March 31, 2023 103.9 million - -
Dec. 31, 2022 110.9 million - -

ATOS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 125.8 million
June 30, 2023 126.6 million
March 31, 2023 126.6 million
Dec. 31, 2022 126.6 million

ATOS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 1000 4.5 million 3.0 million -
June 30, 2023 13000 3.7 million 4.1 million -
March 31, 2023 - 3.5 million 3.6 million -
Dec. 31, 2022 8000 5.0 million 3.2 million -

ATOS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 - 3000
June 30, 2023 - 3000
March 31, 2023 - 3000
Dec. 31, 2022 - 2000

ATOS

Price: $2.01

52 week price:
1.99
19.35

Earnings Per Share: -3.45 USD

P/E Ratio: -1.36

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 530800

Ebitda: -2.0 million

Market Capitalization: 41.8 million

Links: